Extratos Por Fluído Supercrítico

Clique na marca do ingrediente para o seu website

Página Código Nome do Produto Padronização Atividade Funcional

SPATENTES

(1) Black Cumin Seed SCF Extract (Nigellin® )

US 10,881,623: Compositions for the management of hyperglycemia and related conditions.

US 10,945,969: Compositions containing thymohydroquinone and their method of preparation.

(2) Boswellia Extract PS (Boswellin® PS )

EA023717: Use of a composition for down-regulating/inhibiting PGE2.

AU2011200854; CA2732915; I-434696; MX328842: Composition for down-regulating pro-inflammatory markers.

(3) Boswellia Polysaccharides (Polybos®/Polysal® )

US 10,716,823: Adaptogenic compositions and applications thereof.

(4) Cirpusins®

US 10,172,903; US 9,782,450; US 9,387,193; AU2015394033; AU2013292593; CA2883176; EA025578; EP3291805; EP3108935; EP2744571; HK1232483; IDP000062703; JP6759243; JP6135761; KR10-1600212; KR10-1717889; NZ622927; PID201708495; RU2691404; SG11201707106U: Composition comprising Scirpusin A and Scirpusin B and anti-obesity potential thereof.

PH1-2015-500349: Scirpusin A and scirpusin B and anti-obesity potential thereof.

(5) Coleus Forskohlii Extract (ForsLean® )

US 10,085,963; AU2015351423; EP3194575; HK1238675; IDP000071226; JP6472453; KR10-2169620; NZ720422: Process and compositions for achieving mammalian energy balance.

NZ552997: Composition for physiological increase of male and female hormones with diterpene forskolin and its derivatives.

(6) Curcuma Longa Extract WS (uC3 Clear® )

CA2976689; NZ734491; ZA2017/06503: Method to solubilize curcuminoids in water.

(7) Garcinia Extract with Garcinol (GarCitrin® )

US 7,063,861; AU773081; EP1254209; JP4205943; NZ518116: Bioavailable composition of natural and synthetic HCA.

(8) Extrato Seco de Garcinia Indica (Livinol™ )

AU2011352073 ; CA2851663; EP2658374; JP5980228; NZ609878; RU2585245: Hepatoprotectant activity of garcinol.

(9) LivLonga®

US 10,653,643: Liver protectant compositions and therapeutic applications.

(10) Oroxylum Indicum Extract (Sabroxy® )

US 10,407,401: Process for synthesis of oroxylin A

US 10,555,982; CA3043168; JP6851476; NZ753943: Composition containing oroxylin A and method of extraction thereof.

US 10,894,029; JP6796217: Neuroprotective compositions and their use.

EP1986670: Intestinal alpha-glucosidase inhibitors and a process for the isolation and use thereof.

US 7,855,200: Method for treatment of gastric ulcers and ulcers induced by aspirin.

US 10,959,980: Bioactive molecules from Oroxylum indicum and their therapeutic applications.

(11) Pterocarpus Extract WS (pTeroSol® )

IN194292: A process for extraction of antidiabetic formulation mainly containing flavonoid glycosides.

IN192163: process for isolation of novel compound 2, 6-dihydroxy-2-(p-hydroxybenzyl)-3(2H)-benzofuranone-7-C-ß-Dglucopyranoside from Pterocarpus marsupium.

(12) Selenium Enriched Garlic Powder (SelenoForce® )

US 7,014,874: Compositions and methods containing Allium sativum Linn. (garlic) naturally enriched with organic selenium compounds for nutritional supplementation.

AU2006321973; EP1968620; NZ568233: Compositions containing Allium sativum Linn. (garlic) naturally enriched with organic selenium compounds for nutritional supplementation.

(13) Sugarcane Peel Extract (Policosanol )

IN229695: A process for obtaining high purity fatty alcohols.

(14) Terminalia Arjuna Extract – Arjunoglucoside

US 10,479,749:Process for the preparation of standardized composition of arjunoglucoside from the bark of Terminalia arjuna.

(15) Tetrahydrocurcuminoids ODN (Curcumin C3 Reduct® )

EP1328263: Process of making and method of use of tetrahydrocurcuminoids to regulate physiological and pathological events in the skin and mucosa cells.

(16) LactoSpore® + Turmeric Starch (Starmeric™ )

Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof.

(17) Calebina A (CurCousin™ )

US 8,933,121; US 9,328,330; AU2012366253; AU2014203122; CA2857543; JP6374716; KR10-1702702; NZ614076; NZ 715053; RU2543334; SG192695; ZA2013/05918; ZL201280012577.3: Anti-obesity potential of calebin A.

US 9,610,273; US 9,668,999; AU2014202312; CA2850999; CA2963383; EA027148; EP2937084; HK1210590; I-622384; JP6263707; KR10-1647549; NZ624269; MY-170067-A; PH1-2014-000244: Method for the treatment of hypercholesterolemia.

IDP000064827: Calebin A and its effect on hypercholesterolemia.

US 9,220,703; AU2014201769; CA2935898; EP2893926; JP6142446; KR10-1685263; KR10-1685333; MY-175867-A; NZ622909; PH1-2016-501138;

SG11201605336Y: Composition and method for the protection of articular cartilage.

EA027614: Use of calebin A to protect mammalian articular cartilage from pathological damage.

US 9,365,486; AU2014203764; CA2858126; EA027726; EP2963007; HK1217689; JP6490927; KR10-1629561; NZ627247: Synthesis of calebin A and its biologically active analogs.

HK1210028: Calebin A for articular cartilage.

EP3085370: Calebin A for inducing lipolysis.

US 9,737,502; CA2893321; IDP000067993; JP6336943; KR10-1763474; MY-182000-A; PH1-2015-000188; RU2643297; SG10201503805X: Calebin A for hepatic steatosis.

US 9,539,232; CA2941050; RU2653103: Calebin A for osteoporosis.

EP2663185; HK1190874: Calebin A for use in the treatment of inflammation and obesity.

EP3085370: Calebin A for inducing lipolysis.

(18) Oxyresvenox®/Resvenox®

US 7,253,324: Processo de síntese de compostos oxigenados biologicamente ativos por desalquilação dos alquiléteres correspondentes.

(19) Eflornithine Hydrochloride

US 6,998,502; US 7,345,196: Convenient process of manufacture for difluoromethylornithine and related compounds.

(20) DigeZyme®

AU2016428484; JP6857240; ZA2019/02715: Enzyme composition for therapeutic management of muscle soreness.

ZA2019/07676: Enzyme composition for maintenance of metabolic health.

(21) LactoSpore®

US 10,668,115: Stable probiotic compositions containing Bacillus coagulans MTCC 5856 and method of detection thereof.

US 10,609,935: Beverage compositions containing Bacillus coagulans MTCC 5856.

US 9,579,352: Process for the therapeutic management of diarrhea predominant irritable bowel syndrome using Bacillus coagulans.

US 10,166,261; AU2016413572; CA3023818; ZL2019/00501: Bacillus coagulans MTCC 5856 for the management of major depressive disorder.

US 10,260,112; CA2999517; EP3356545; MY-185340-A: Novel PCR primers and methods thereof for the identification of Bacillus coagulans MTCC 5856.

EA037312; EP3240553; JP6629875; KR10-2157043; MY-182658-A; ZL 201680008035.7: Process for the therapeutic management of diarrhea predominant irritable bowel syndrome using Bacillus coagulans SBC37-01, MTCC 5856.

US 10,806,760: Compositions and methods for reducing flatulence.

US 10,293,008; AU2015308650; EA034017; EP3185877; HK1233174; IDP000066793; JP6630723; KR10-2089566; MX376004; MY-174855-A; SG11201700006U; ZL201580042813.X: Process for enhancing the viable counts of lactic acid bacteria and useful composition thereof.

US 10,792,295; JP6839329: Composition for management of Helicobacter pylori infection.

RU2745755: Anti-pollution compositions containing Bacillus coagulans.

(22) LactoCran®

US 9,717,766: Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof.

(23) PeptiSeLect®

US 8,193,156: Dipeptides incorporating selenoamino acids with enhanced bioavailability—synthesis, pharmaceutical and cosmeceutical applications thereof.

(24) MethySelene®

US 6,794,537: Manufacturing processes for Se-methyl-L-selenocysteine.

US 6,982,273: Compositions and methods containing bioavailable Se-methyl-L-selenocysteine for human and veterinary use.

(25) Metabolicgard®

US 10,477,886; US 10,258,073: Functional nutritional blend for thermo-metabolic performance.

(26) WithanAlpha™

US 10,864,242: Aphrodisiac composition and management of male sexual dysfunction.

(27) ZeaLutein®

US 6,689,400: Process of obtaining compositions of stable lutein and lutein derivatives.

Isenção de responsabilidade

Estas afirmações ainda não foram avaliadas pelo FDA. Estes produtos não foram desenvolvidos para diagnosticar, tratar, curar ou prevenir doenças.

    VISIT US

  • Edifício Koerich Beiramar Office
    Avenida Mauro Ramos
    1970- Sala 705-Centro
    Florianópolis-SC
    Brasil CEP 88.020-302

  • +55 48 3206 3682
  • info@sabinsa.com.br

Certificados

Certificate Logos Certificate Logos
Certificate Logos Certificate Logos

Fale Conosco